메뉴 건너뛰기




Volumn 349, Issue , 2014, Pages

Bias related to funding source in statin trials: The biases are clear if you know where to look

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

EID: 84907661955     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g5949     Document Type: Editorial
Times cited : (5)

References (13)
  • 1
    • 84907661954 scopus 로고    scopus 로고
    • Industry sponsorship bias in research findings: A network meta-analysis of LDL cholesterol reduction in randomised trials of statins
    • Naci H, Dias S, Ades AE. Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. BMJ 2014;349:g5741.
    • (2014) BMJ , vol.349 , pp. g5741
    • Naci, H.1    Dias, S.2    Ades, A.E.3
  • 2
    • 34347243202 scopus 로고    scopus 로고
    • Factors associated with findings of published trials of drug-drug comparisons: Why some statins appear more efficacious than others
    • Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLOS Med 2007;4:e184.
    • (2007) PLOS Med , vol.4 , pp. e184
    • Bero, L.1    Oostvogel, F.2    Bacchetti, P.3    Lee, K.4
  • 4
    • 0028115828 scopus 로고
    • A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis
    • Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 1994;154:157-63.
    • (1994) Arch Intern Med , vol.154 , pp. 157-163
    • Rochon, P.A.1    Gurwitz, J.H.2    Simms, R.W.3    Fortin, P.R.4    Felson, D.T.5    Minaker, K.L.6
  • 5
    • 33644994132 scopus 로고    scopus 로고
    • Why olazepine beats risperidone, risperidone beats quetiapine, and quetiapine beats olazepine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics
    • Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olazepine beats risperidone, risperidone beats quetiapine, and quetiapine beats olazepine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006;163:185-94.
    • (2006) Am J Psychiatry , vol.163 , pp. 185-194
    • Heres, S.1    Davis, J.2    Maino, K.3    Jetzinger, E.4    Kissling, W.5    Leucht, S.6
  • 6
    • 0036742342 scopus 로고    scopus 로고
    • Design and reporting modifications in industry sponsored comparative psychopharmacology trials
    • Safer DJ. Design and reporting modifications in industry sponsored comparative psychopharmacology trials. J Nerv Ment Dis 2002;190:583-92.
    • (2002) J Nerv Ment Dis , vol.190 , pp. 583-592
    • Safer, D.J.1
  • 7
    • 0033544292 scopus 로고    scopus 로고
    • Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis
    • Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999;282:1752-9.
    • (1999) JAMA , vol.282 , pp. 1752-1759
    • Johansen, H.K.1    Gøtzsche, P.C.2
  • 8
    • 42249100174 scopus 로고    scopus 로고
    • Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: A case study based on documents from rofecoxib litigation
    • Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA 2008;299:1813-7.
    • (2008) JAMA , vol.299 , pp. 1813-1817
    • Psaty, B.M.1    Kronmal, R.A.2
  • 11
    • 84858996695 scopus 로고    scopus 로고
    • Effect of reporting bias on meta-analyses of drug trials: Reanalysis of meta-analyses
    • Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ 2012;343:d7202.
    • (2012) BMJ , vol.343 , pp. d7202
    • Hart, B.1    Lundh, A.2    Bero, L.3
  • 12
    • 84897368196 scopus 로고    scopus 로고
    • Why the Cochrane risk of bias tool should include funding source as a standard item[editorial]
    • ED000075
    • Bero LA. Why the Cochrane risk of bias tool should include funding source as a standard item [editorial]. Cochrane Database Syst Rev 2013;12:ED000075.
    • (2013) Cochrane Database Syst Rev , vol.12
    • Bero, L.A.1
  • 13
    • 84866146413 scopus 로고    scopus 로고
    • Corporate manipulation of research: Strategies are similar across five industries
    • White J, Bero LA. Corporate manipulation of research: strategies are similar across five industries. Stanford Law Policy Rev 2010;21:105-34.
    • (2010) Stanford Law Policy Rev , vol.21 , pp. 105-134
    • White, J.1    Bero, L.A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.